Integral Investment Advisors Inc. Has $325,000 Position in AbbVie Inc. (NYSE:ABBV)

Integral Investment Advisors Inc. lowered its stake in shares of AbbVie Inc. (NYSE:ABBV) by 5.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 1,829 shares of the company’s stock after selling 109 shares during the period. Integral Investment Advisors Inc.’s holdings in AbbVie were worth $325,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Tradewinds Capital Management LLC raised its position in shares of AbbVie by 838.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,221 shares of the company’s stock valued at $750,000 after buying an additional 3,771 shares during the last quarter. New England Capital Financial Advisors LLC raised its position in shares of AbbVie by 117.1% during the fourth quarter. New England Capital Financial Advisors LLC now owns 788 shares of the company’s stock valued at $140,000 after buying an additional 425 shares during the last quarter. Kooman & Associates raised its position in shares of AbbVie by 6.1% during the fourth quarter. Kooman & Associates now owns 3,411 shares of the company’s stock valued at $606,000 after buying an additional 195 shares during the last quarter. TCW Group Inc. increased its stake in AbbVie by 5.1% in the fourth quarter. TCW Group Inc. now owns 424,283 shares of the company’s stock valued at $75,395,000 after acquiring an additional 20,645 shares during the period. Finally, ST. Nicholas Private Asset Management Inc. bought a new stake in AbbVie in the fourth quarter valued at about $6,782,000. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Activity

In related news, SVP Kevin K. Buckbee sold 1,800 shares of the stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total value of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at $1,202,751.92. This represents a 20.49 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. 0.25% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on ABBV shares. Leerink Partners raised shares of AbbVie from a “market perform” rating to an “outperform” rating and set a $206.00 target price on the stock in a research note on Friday, November 22nd. Daiwa America cut shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Thursday, December 5th. UBS Group upped their target price on shares of AbbVie from $181.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Wells Fargo & Company upped their target price on shares of AbbVie from $195.00 to $210.00 and gave the company an “overweight” rating in a research note on Monday, February 3rd. Finally, Leerink Partnrs raised shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 22nd. Five research analysts have rated the stock with a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $208.35.

AbbVie Price Performance

ABBV opened at $202.03 on Friday. AbbVie Inc. has a one year low of $153.58 and a one year high of $207.32. The company has a debt-to-equity ratio of 17.94, a current ratio of 0.66 and a quick ratio of 0.54. The company’s 50 day simple moving average is $181.25 and its 200-day simple moving average is $186.42. The stock has a market capitalization of $356.64 billion, a P/E ratio of 84.18, a price-to-earnings-growth ratio of 1.61 and a beta of 0.58.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, January 31st. The company reported $2.16 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a net margin of 7.59% and a return on equity of 296.28%. During the same quarter in the prior year, the firm earned $2.79 EPS. Sell-side analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, May 15th. Stockholders of record on Tuesday, April 15th will be paid a dividend of $1.64 per share. The ex-dividend date of this dividend is Tuesday, April 15th. This represents a $6.56 annualized dividend and a dividend yield of 3.25%. AbbVie’s dividend payout ratio (DPR) is currently 273.33%.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.